Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Production & Manufacturing
Manufacturing
Return to: PBR Home | Production & Manufacturing | Manufacturing

Astellas Pharma to transfer Intal rights to Sanofi-aventis

PBR Staff Writer Published 19 October 2010

Astellas Pharma is set to transfer the rights to distribute the anti-allergic drug Intal (sodium cromoglycate) to Sanofi-aventis effective on 1 January 2011.

Astellas Pharma is also expected to transfer the manufacturing and marketing approval for all Intal products to Sanofi-aventis as of 1 October 2010.

Intal is a chemical mediator release inhibitor discovered by the British company Fisons (currently Sanofi-aventis Group) and has seven different formulations.

Intal is indicated for a wide range of allergic diseases, such as allergic conjunctivitis/vernal conjunctivitis, allergic rhinitis, atopic dermatitis caused by food allergies and bronchial asthma.

Comments
Post a comment

Comments may be moderated for spam, obscenities or defamation.